InDex Pharmaceuticals Holding AB Share Price

Equities

INDEX

SE0008966295

Pharmaceuticals

Market Closed - Nasdaq Stockholm 16:29:49 26/04/2024 BST 5-day change 1st Jan Change
0.368 SEK +5.14% Intraday chart for InDex Pharmaceuticals Holding AB +11.85% +43.75%

Financials

Sales 2024 * - Sales 2025 * - Capitalization 196M 2.14B 15.69B
Net income 2024 * -259M -2.83B -20.73B Net income 2025 * -221M -2.42B -17.69B EV / Sales 2024 * -
Net Debt 2024 * 86.32M 944M 6.91B Net Debt 2025 * 306M 3.35B 24.48B EV / Sales 2025 * -
P/E ratio 2024 *
-0.75 x
P/E ratio 2025 *
-0.9 x
Employees 7
Yield 2024 *
-
Yield 2025 *
-
Free-Float 62.47%
More Fundamentals * Assessed data
Dynamic Chart
InDex Pharmaceuticals Holding AB Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Index Pharmaceuticals Holding AB Announces Board Resignations CI
InDex Pharmaceuticals CEO, CFO to Step Down as Operations Cease MT
Index Pharmaceuticals Holding AB Announces Resignation of Johan Giléus as Deputy CEO CI
InDex Pharmaceuticals Holding AB Announces Resignation of Jenny Sundqvist as CEO, Effective September 26, 2024 CI
InDex Pharmaceuticals Holding AB Announce Resignation of Johan Giléus as CFO, Effective September 26, 2024 CI
InDex Pharmaceuticals Launches Strategic Review Amid Decision to Stop Cobitolimod Development MT
InDex Pharmaceuticals Holding AB Discontinues the Development of Cobitolimod CI
InDex Pharmaceuticals Holding AB Reports Earnings Results for the Full Year Ended December 31, 2023 CI
InDex Pharmaceuticals Holding AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
InDex Pharmaceuticals Holding AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
InDex Pharmaceuticals Holding AB Discontinues Cobitolimod Phase III Program CI
InDex Pharmaceuticals Holding AB Announces Composition of the Nomination Committee CI
InDex Pharmaceuticals Obtains South Korean Patent for Inflammatory Bowel Disease Drug Candidate MT
InDex Pharmaceuticals Holding AB Receives New Patent for Cobitolimod in South Korea CI
More news
1 day+5.14%
1 week+11.85%
Current month+26.03%
1 month+23.49%
3 months+53.97%
6 months-53.42%
Current year+43.75%
More quotes
1 week
0.32
Extreme 0.32
0.37
1 month
0.29
Extreme 0.286
0.37
Current year
0.22
Extreme 0.22
0.37
1 year
0.20
Extreme 0.198
0.93
3 years
0.20
Extreme 0.198
1.99
5 years
0.20
Extreme 0.198
12.70
10 years
0.20
Extreme 0.198
12.70
More quotes
Managers TitleAgeSince
Chief Executive Officer 53 31/12/22
Director of Finance/CFO 59 30/04/17
Chief Tech/Sci/R&D Officer 45 -
Members of the board TitleAgeSince
Director/Board Member 74 31/12/15
Director/Board Member 68 31/12/10
Chairman 72 31/12/10
More insiders
Date Price Change Volume
26/04/24 0.368 +5.14% 4,428,624
25/04/24 0.35 -1.96% 3,435,634
24/04/24 0.357 +2.59% 1,927,297
23/04/24 0.348 -0.29% 1,484,683
22/04/24 0.349 +6.08% 5,708,429

Delayed Quote Nasdaq Stockholm, April 26, 2024 at 04:29 pm

More quotes
InDex Pharmaceuticals Holding AB is a Sweden-based company, which is primarily engaged in the healthcare industry. The Company is focused in pharmaceuticals development. The Company's drug candidate is cobitolimod that helps in ulcerative colitis treatment. In addition, the Company develops a platform of patent protected substances, DNA based ImmunoModulatory Sequences (DIMS), that helps in the treatment of various immunological diseases. The Company also offers diagnostic kit DiBiCol, which is a PCR-based method that monitors seven biomarkers specific for ulcerative colitis or Crohn’s disease from a single colonic biopsy. InDex Pharmaceuticals Holding AB operates as a parent for InDex Pharmaceuticals AB and InDex Diagnostics AB. Among the Company's shareholders are SEB Venture Capital, Industrifonden and NeoMed Management.
Calendar
More about the company
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
0.368 SEK
Average target price
0.535 SEK
Spread / Average Target
+45.38%
Consensus

Annual profits - Rate of surprise